[THE INVESTOR] Hugel, a Korean botulinum toxin (BTX) manufacturer, patented technology to develop patch type BTX at home, potentially rendering the injection type BTX as antiquated.
The biopharmaceutical firm announced on Jan.9 that it has secured and patented the technology to develop adhesive BTX patches with micro needles coated with botulinum toxin, which may prickle, but are nowhere nearly as obviously felt on the skin as needle injection.
The scope of Hugel’s patented technology spans micro needle, micro blade, micro knife and more, modeling botulinum toxin as according to how it should be applied to penetrate the skin in patch form.
Hugel plans to apply the patented technology to run clinical trials of patch type botulinum toxin and potentially commercialize it. It also is mulling international patent of the technology.
Patch type BTX can have the option of minute adjustment of the concentration of BTX, and precision application of the patch. Its biggest advantage, of course, is the significantly decreased level of pain on patient, the firm said.
“This patented technology will greatly contribute to Hugel’s future global market sales expansion and safe and convenient use of BTX across cosmetic and therapeutic field,“ Hugel’s CEO Sohn Ji-hoon said.
“Hugel will establish itself as a leading global research and development firm through continued development of various types of BTX,” he said.
By Lim Jeong-yeo/The Korea Herald (firstname.lastname@example.org)